This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
United Airlines (UAL) to Sack Workers on Vaccine Refusal Grounds
by Zacks Equity Research
The 593 workers of United Airlines (UAL) have not applied for exemption from getting jabbed on medical or religious grounds.
5 Winning Global ETFs of First Nine Months of 2021
by Sanghamitra Saha
Global markets have rallied this year on return of the risk-on sentiments. However, rising rate worries caused occasional turmoil in the market in September.
5 Top ETF Stories of Nine Months of 2021
by Sweta Killa
We discuss some of the hot events of the first nine months of this year that influenced the market in a big way.
Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA
by Zacks Equity Research
Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.
Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP
by Zacks Equity Research
Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.
Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data
by Zacks Equity Research
Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.
Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC
by Zacks Equity Research
Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies
by Zacks Equity Research
Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.57, marking a -0.84% move from the previous day.
AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.
OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed
by Zacks Equity Research
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis
Top Research Reports for Home Depot, salesforce & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE).
AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space
by Zacks Equity Research
AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing
by Zacks Equity Research
On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility
Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only
by Zacks Equity Research
The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.
7 Best ETFs of the First Nine Months of 2021
by Sweta Killa
We highlight seven ETFs from different segments that have outperformed and gained more than 40% in the first nine months of 2021.
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
Nike, Costco Report Better Earnings than Expected
by Mark Vickery
Both Nike and Costco beat bottom-line estimates in their subsequent quarters, but struggled to match on the top-line.
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
by Zacks Equity Research
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.